Betsy Hanna
Chief Executive Officer
|
Betsy Hanna is a healthcare and biotech leader. Most recently she was Clinical Genomics’ chief commercial officer with responsibility for developing and executing go-to-market strategies. Ms. Hanna has two decades of healthcare industry experience including strategic marketing, U.S. and international sales management, and product launch. She joined Clinical Genomics from Origin, Inc., a clinical-stage biotech company where she was the president and chief operating officer. Prior to Origin, Ms. Hanna had increasing responsibility during eight years at Johnson & Johnson. At J&J diagnostics, she was vice president, strategic marketing and led the global launch of two instrument platforms. At J&J diagnostics, Hanna also served as vice president Europe, Mideast and Africa and, for J&J Vision Care, was vice president of strategic marketing and a member of the global management board. Ms. Hanna has a BS in Chemical Engineering from the University of Illinois and an MBA from Harvard Business School.
|
Lawrence LaPointe, PhD
Chief Innovation Officer
|
Larry LaPointe, PhD, has more than two decades building healthcare companies to transform cancer testing, including most recently as co-founder of Clinical Genomics. He previously served as CTO and general manager of Enterix Inc, a cancer screening company he also co-founded. Dr. LaPointe is a well-published research scientist and holds numerous patents in biomarker discovery, cancer detection and molecular diagnostics. He has a BS in Biology from Florida State University and a PhD in Bioinformatics from Flinders University, Australia.
|
Robert Bruce
Vice President, Reimbursement
|
Mr. Bruce has over 25 years of experience advising and serving in senior management roles (CFO, COO, CEO, Director) for a range of private and public companies operating in highly-regulated industries, including healthcare, energy production, telecommunications and gaming. Prior to joining Clinical Genomics, he founded and led Oakmont Advisory Group, a financial and management consulting group serving a wide range of investors, lenders and shareholders in their efforts to improve operational and financial execution at client companies. Among his previous positions, he served as COO and VP of Reimbursement at Enterix and led the company’s efforts to secure regulatory approvals and reimbursement for the InSure® FIT test. He holds a BA in East Asian Studies from Princeton University (phi beta kappa; summa cum laude) and an MBA from the Yale University School of Management.
|
Susanne K. Pedersen, PhD
Vice President, Science and Innovation (CSO) and Co-Founder
|
Susanne Pedersen has deep commercial experience focused on biomarker discovery and validation including product concept to successful commercial launch. IVD assay expertise includes molecular diagnostics, proteomics, and immunoassays in esoteric pathology labs as well as point of care testing. Since 2010, her concentrated expertise has been in epigenetics and cell free DNA measurements for cancer detection. Dr. Pedersen is the Inventor of biomarker discovery patents and has a successful track record building cross-functional teams that meet commercial milestones including scale up. B.Sc. (Cell Biology; Southern University of Denmark, 1996); Ph.D. (Molecular Biology; Southern University of Denmark; 2000).
|